she lost her voice for two weeks; second dose the itching began immediately and she ended up with a rash and hives, and then she lost her voice for two weeks; second dose the itching began immediately and she ended up with a rash and hives, and then she lost her voice for two weeks; second dose the itching began immediately and she ended up with a rash and hives, and then she lost her voice for two weeks; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 50-year-old female patient received BNT162b2 (BNT162B2), on 02Dec2021 as dose 2, single (Batch/Lot number: unknown) at the age of 50 years for covid-19 immunisation. The patient's relevant medical history included: "Allergy" (unspecified if ongoing); "Retinopathy of prematurity" (unspecified if ongoing); "COVID" (unspecified if ongoing); "autoimmune issues" (unspecified if ongoing); "health issues" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Gentamicin, reaction(s): "gentamicin allergy". Vaccination history included: BNT162b2, administration date: 09Nov2021, when the patient was 50-year-old, for Covid-19 immunization, reaction(s): "She says she had itching after the first dose". The following information was reported: RASH (non-serious), PRURITUS (non-serious), URTICARIA (non-serious) all with onset Dec2021, outcome "unknown" and all described as "second dose the itching began immediately and she ended up with a rash and hives, and then she lost her voice for two weeks"; APHONIA (non-serious) with onset Dec2021, outcome "recovered", described as "she lost her voice for two weeks". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of aphonia, rash, pruritus, urticaria.  Additional information: The patient was allergic to Gentamicin sometime between 1989-2000. She was born two months early, and has been blind since birth, she has ROP or retinopathy of prematurity. She had COVID twice and was in the hospital in the ICU the first time. Her weight varied quite a bit from time to time. She stated that, at the time she had weighed less, she had a lot of fluid retention problems. She also stated that she had itching after the first dose, but not right way, and then it went away after taking Benadryl for a day or two. She had itching after the dose and took Benadryl as a treatment, she thought that she took two 25mg tablets at a time, and she also took some Aller-Tec, which was like a version of Zyrtec, she took that two to three times a day as well for about a week or two maybe. She said that she lost her voice for two weeks and couldn't work. She said her treatment for losing her voice was no talking and taking allergy meds. She reported it to her allergist when she saw them, and they didn't seem to think it was major, but to her it was a reaction to the vaccine. She said the itching then losing her voice occurred immediately after her second dose and was an allergy in her opinion. The rash and hives after the second dose began immediately, and she was treated with the high doses of Benadryl.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200742489 similar report from same reporter